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This is a briefoverview ofthe development ofcancer therapy with afocus on systemic therapy. The
modem era ofchemotherapy developed at Yale University Medical School during World War II, a
fact that has been generally unrecognized until recently. The observations preceding and involved
in the discovery ofeffective drugsfor cancer seemparticularly pertinentfor this anniversary year
While the modern era of cancer
chemotherapy began following the World
War II, the origins of cancer treatment are
recorded in ancient documents. Although
most treatments for advanced cancer were
ineffective until the nineteenth century, it
is of interest to review some pertinent
examples of the volution of cancer thera-
PY.
The Ebers papyrus, the Edwin Smith
papyrus, and the Ramayana describe ma-
lignant diseases and their treatments [1-3].
Most frequently, therapy consisted of topi-
cal preparations although removal of neo-
plasms had been practiced in antiquity [2].
Mastectomy was described during the
Roman period by Celsus and Leonides [4].
Dioscorides, in the first century A.D.,
compiled a listing of medicinal herbs and
botanicals, including topical applications
for treatment of tumors and carcinomata
[5]. These treatments were in use for 15
centuries [6].
In the eleventh century an Arabic
physician, Ibn Sina, known in the West as
Avicenna, used arsenical therapy systemi-
cally, although it was found to be danger-
ous and received little attention [7].
Arsenical preparations known as
Unguentum Aegypticum were used topi-
cally until the sixteenth century [6].
Many consider the use of potassium
arsenite to treat chronic myelogenous
leukemia in 1865 by Lissauer as the first
instance of effective chemotherapy for
malignant disease [8]. The patient
improved, but no blood counts were
obtained, and it was only after 13 years
that the beneficial effects on the peripher-
al blood were reported [9]. The use of
arsenicals (Fowler's solution) to treat
leukemias continued until the 1930s [10].
The past decade has witnessed a return to
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the use of arsenical therapy, such as
arsenic trioxide, which is now established
as a very effective treatment for acute
promyelocytic leukemia [11, 12].
Radiation therapy was undoubtedly
the most effective form of antitumor treat-
ment besides surgery for almost the first
half of the twentieth century. Following
Roentgen's discovery of x-rays, radiation
therapy developed rapidly, although the
methodology was primitive as compared
to present day standards [13]. In the
United States, Pusey and Senn reported
results in treatment of lymphomas and
leukemia in 1902 and 1903 [14, 15]. In
some instances, the results were dramatic
and suggested cures, although thedevelop-
ment of relapse of disease and complica-
tions of treatment quickly altered the ini-
tial optimism.
Within a year of Roentgen's publica-
tion regarding the discovery of x-rays,
another report of effective antitumor ther-
apy appeared. Beatson, writing in the
Lancet in 1896, noted benefit following
oophorectomy in three patients with inop-
erable carcinoma of the breast [16]. The
rationale for the use ofoophorectomy was
not because of any known hormonal
effects recognized at that time. Hormonal
mechanisms were, however, elucidated
almost 50 years later when the role of
androgens in prostate cancer was
described by Huggins [17].
Over the centuries, numerous nos-
trums were tried for systemic neoplastic
disease. In 1767, Burrows (A New
Practical Essay on Cancers, London)
summarized, "that whatever has been pro-
posed for the curing of cancers, are mere-
ly palliative medicines; and that no real
specific has been hitherto discovered for
that fatal disorder, although the physicians
of all nations, from the time of
Hippocrates to the present, have, by num-
berless researches and experiments, made
trial of every thing in nature, from the
most innocent drug, to the most virulent
poison, both in the mineral and vegetable
kingdoms; yet the disease still baffles the
power of physic" [18]. Similar views are
stated in 1914 when Bainbridge wrote,
"Throughout the centuries, the sufferers of
this disease have been the subject of
almost every conceivable form of experi-
mentation. The fields and forests, the
apothecary shop and temple have been
ransacked for some successful means of
relief from the intractable malady. Hardly
any animal had escaped making its contri-
bution to hide orhair, tooth ortoenail, thy-
mus or thyroid, liver or spleen, in the vain
search for a means ofrelief' [19].
Late in the nineteenth century a sur-
geon, William Coley, developed a mixture
ofbacterial toxins known as Coley's toxin
which induced regression of some tumors
[20]. Other sera and bacterial toxins were
developed, since one theory of the causa-
tion of cancer was the concept of some
unidentified organism as a causative agent
[21].
Other therapeutic measures included
blood transfusions, splenectomy, thy-
roidectomy, oxygen therapy, fever therapy,
pituitary extract, and the use of organ
extracts such as extracts of animal spleen,
bone marrow, lymph nodes, pancreas,
stomach, and small intestine [19].
Vitamins and minerals were also adminis-
tered. Starvation diets were recommended
by some physicians on the basis of the
observation ofcachexia in cancer patients,
considered to be beneficial by depriving
the tumor of nutritional needs [22].
The lack ofeffective treatment did not
deter claims for treatment benefits. Bryant,
writing in the Boston Medical and
Surgical Journal (1921), stated, "decided
advances have been made in the past fif-
teen years and cancer may now be consid-
ered a somewhat preventable, somewhat
curable disease" [23]. In 1920, however, in
an editorial in the Canadian Practitioner
and Review, the author commented on
publicity arising from the use of an anti-Papac: Origins ofcancer therapy 393
cancer serum, "the newspapers are full of
the most objectionable items published in
wholesale style, such as "cancer patients
are markedly better" and "all are
improved." From the standpoint of the
patients alone, this is unadvisable, if not
absolutely cruel" [24].
However, during the 1920s and 1930s
an important advance that aided in the
development of the modem era of cancer
treatment was the development of animal
systems that were to be predictive for anti-
tumor drugs [25-27]. These systems laid
the groundwork for subsequent drug
screening programs.
The origins ofeffective chemotherapy
for cancer date to World War I when mus-
tard gas (sulfur mustard) was used. The
blood and bone marrow findings in cases
of mustard gas poisoning were described
by Krumbhaar and later by Krumbhaar
and Krumbhaar in 1919 [28, 29]. The time
sequence of marrow depression revealed a
maximal effect at two weeks after expo-
sure when mortality was highest. Deaths
were attributed in some cases to pneumo-
nia associated with leucopenia. Autopsies
revealed atrophy of lymphoid and testicu-
lar tissue as well as hypoplasia ofthe bone
marrow.
In 1929, Berenblum, in studying car-
cinogenesis, observed that sulfur mustard
was "anti-carcinogenic" [30]. In attempt-
ing to enhance the development of tumors
induced by a carcinogenic tar, Berenblum
and Riley-Smith added a solution of mus-
tard gas, assuming that the local irritant
effect of the mustard gas would induce
hyperemia that was beneficial to tumor
development. As described by the authors,
the result was diametrically opposite. The
mustard gas application inhibited the
induction of tumors, and further experi-
ments suggested that this was mediated by
an effect of mustard gas on the animal
rather than some interaction with the car-
cinogenic substance. Berenblum and
Riley-Smith continued to investigate the
"anticarcinogenic" effects of mustard gas,
observing that inhibition of tumors
induced by other carcinogens such as
dibenzanthracene also occurred with mus-
tard gas [31]. Other topical irritants were
studied for tumor inhibition, and the only
other agent not closely related to mustard
gas with some tumor inhibitory activity
was noted to be cantharidin.
Recognition of the possible impor-
tance ofsulfur mustards in cancerresearch
was later cited. Dr. James Ewing at the
Memorial Hospital in New York recom-
mended the study ofthe effects ofmustard
gas on experimental tumors, reported in
1931 [32]. Adair and Bagg applied a solu-
tion of mustard gas to the skin of normal
mice and to atumor induced by a chemical
carcinogen [32]. Tumor regression was
evident in the cutaneous tumor although
autopsy showed a metastatic lung nodule
in the animal. Varying doses of mustard
gas application to the skin of the rabbit
were assessed to determine appropriate
doses for local use. This was followed by
the application of topical mustard gas to
cutaneous lesions of twelve patients and
intratumoral injection in one individual at
the Memorial Hospital in New York and
reported by Adair and Bagg in 1931. The
results included a "violent therapeutic
reaction" and virtual disappearance of
tumor after the intratumoral injection. The
tumors studied included melanoma, squa-
mous cell carcinoma of the skin, neurofi-
broma, neurogenic sarcoma and two cases
ofpenile carcinoma.
All showed regression for a period of
months: there was no long-term follow up
reported, and a cautionary statement
warned that intratumoral injection
required care since destruction of vital
parts could ensue. The authors concluded
that mustard gas solution represented
another agent for treatment of localized
cancer.
Despite this work, which is seldom
cited, it was well over a decade before394 Papac: Origins ofcancer therapy
alkylating agent therapy was introduced
into clinical use. Topical use of the nitro-
gen mustards was not practiced until 1956
when it was found to be useful for myco-
sis fungoides [33].
The advent of World War II stimulat-
ed furtherresearch on chemical warfare. A
series of analogues of sulfur mustards
were produced as potential offensive
agents. It was recognized that beta
chlorethyl amines could exert cytotoxic
actions on a variety oftissues, particularly
related to the degree of their proliferative
activity. Further study ofthe basic mecha-
nisms of cellular effects of the sulfur and
nitrogen mustards suggested that their
effects resembled those ofx-rays.
Since the data were classified during
wartime, these findings were reported fol-
lowing World War II by Goodman and
Philips from the Pharmacology Section,
Medical Division ofthe Chemical Warfare
Service ofthe U.S. Army [34]. It was sug-
gested that the clinical application to neo-
plastic disease was possible. In fact, in
1942, Gilman, Goodman, Philips, and
Allen at Yale discovered the antitumor
activity of nitrogen mustard (methyl-bis)
(beta-chlorethyl) (amine hydrochloride)
[35]. The use of these compounds was
restricted due to war time secrecy; hence
the publication was delayed until 1946.
Interestingly, major textbooks of can-
cer medicine have erroneously attributed
the initial use ofnitrogen mustard to find-
ings of exposure to mustard gas following
an explosion that occurred in Bari Harbor
in 1943 [36, 37]. The initial clinical trial
occurred atYale in May 1942 [35].
The initial clinical trial of nitrogen
mustard was reviewed by Gilman almost
20 years later [35]. He stressed that prior
to clinical trial there were thorough animal
studies conducted. Pharmacologic studies
ofthe nitrogen mustard in rabbits revealed
a remarkable sensitivity of lymphoid tis-
sues to cytotoxic action of the nitrogen
mustards.
It seemed natural, therefore, to exam-
ine the susceptibility of lymphoma to the
nitrogen mustards. Gilman, Goodman, and
Philips who had made the observations in
rabbits turned to Thomas Dougherty, an
anatomist, who first studied the com-
pounds in mice, to ascertain the lethal dose
and bone marrow effects. Doughtery, who
was working with Gardner on a transplant-
ed lymphoma, originally from an estrogen
treated mouse, ultimately known as the
Gardner lymphosarcoma, tried nitrogen
mustard in a mouse with an advanced
tumor. The tumor began to regress after
two injections and became impalpable.
The tumor recurred and was successfully
treated although there was less regression
than noted with the initial treatment. The
animal, whose survival with this type of
tumor was generally three weeks, survived
for 84 days.
The observation was followed by test-
ing in several other animal lymphomas
and leukemias. None demonstrated the
striking effect noted in the Gardner lym-
phosarcoma, and in some the treatment
was completely ineffective. Gilman later
wrote, "I have often thought that ifwe had
by accident chosen one of these
leukemias, in which there was absolutely
no therapeutic effect, we might possibly
have dropped the whole project" [34]. This
serendipitous choice was paralleled in the
human trial that followed.
In May 1942, a therapeutic trial in
man was carried out under the supervision
of Dr. Gustav E. Lindskog, an Assistant
Professor of Surgery. The patient was
described as "an x-ray resistant patient in
the terminal stages of lymphosarcoma."
The patient was a man, aged 48, who had
received radiation therapy in March 1941
with considerable reduction in tumor
involving the right tonsil, cervical nodes
and axilla as well as mediastinum. In
December 1941, he had recurrent disease
treated by radiation therapy. In May 1942,
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the disease which now was associatedwith
neck and facial edema, venous dilatation
of the upper chest, and inability to adduct
his arms due to large axillary masses.
During this treatment, the patient did not
respond to the radiation, so ten consecu-
tive daily doses of nitrogen mustard 0.1
mg/kg were administered daily for 10
days.
On the fourth day of therapy,
improvement was noted and by the last
day of treatment, all signs and symptoms
of his disease were gone. The response of
thepatient was striking and very much like
the observations in the animal tumor.
The patient relapsed after one month,
was then treated with a lesser dose (he
experienced severe leuconeutropenia after
the initial treatment) as well as throm-
bopenia (22,000 platelets/mm3) and some
cutaneous purpura. He received a third
course three weeks later to which he did
not respond.
These observations generated consid-
erable excitement and were followed by
treatment of several patients who were in
the terminal stages ofmalignant disease in
a variety of tumors. Early reports docu-
mented some dramatic responses in
Hodgkin's disease patients who had
become refractory to radiation therapy. An
example is the case of a 33-year-old
woman who presented with dyspnea,
cough, motor and sensory paresis of the
right arm, and adenopathy of the axilla,
neck and mediastinum. The patient also
had edema of the breasts, and fevers to
103°F. Following four doses of nitrogen
mustard at 0.1 mg/kg, improvement devel-
oped with disappearance of fever, dysp-
nea, and cough. The edema of her arms
and breasts receded completely with 75
percent reduction in adenopathy.
As in the animal experiments, some
tumors were resistant to the treatment. The
clinical results in the acute leukemias were
disappointing. No benefit was noted in
melanoma, cervical carcinoma, and some
lymphoma patients.
As expected from the animal data,
bone marrow depression was amajortoxic
effect ofthe treatment. In the animal stud-
ies, the bone marrow suppression was
reversible, and a fairly wide margin exist-
ed between marrow suppressive and lethal
doses. As noted, the initial human dose
was 0.1 mg/kg daily for 10 days. At three
weeks following treatment, the total white
count was 200 cu/mm and severe throm-
bopenia was noted. In man, the marrow
recovery was prolonged in some instances,
so dose modifications were utilized. The
standard dose evolved to 0.1 mg/kg for
four days.
It is noteworthy that Wilkinson and
Fletcher in England began independent
clinical trials with nitrogen mustards in
1942 but did not publish the data until
1947 [38], citing the restrictions of secre-
cy during the war. From their report it is
unclear what constituted the stimulus for a
clinical trial apart from a similarity of the
hematopoietic effects to those producedby
x-rays. Eighteen patients were treated
including eight with chronic myelogenous
leukemia, three with chronic lymphocytic
leukemia, four with Hodgkin's disease,
and three with polycythemia vera. The tris
compound was utilized rather than the bis
compound used in the American studies.
The doses applied were smaller than those
used atYale. The most striking benefit was
noted in chronic myelogenous leukemia,
although significant benefit was observed
in Hodgkin's disease.
Between 1943 and 1946 clinical stud-
ies with nitrogen mustard were extended
to include Leon Jacobson in Chicago,
Maxwell Wintrobe at Salt Lake City,
William Dameshek in Boston, and
Cornelius Rhoads and David Karnofsky in
New York [39-41]. In 1946, C.P. Rhoads
who was chairman of the Committee on
Growth of the National Research Council
reported the findings in the Journal of the396 Papac: Origins ofcancer therapy
American Medical Association [42]. The
conclusion was that the nitrogen mustards
were not a cure for neoplastic diseases and
the tumor regressions were temporary. It
was suggested that laboratory and clinical
studies should continue in the hope that
certain types of cancer might prove to be
unusually sensitive to these agents and that
compounds with more selective action on
cancer tissue might be discovered.
During the period of the development
of nitrogen mustards, the era of effective
antibiotic therapy for infectious diseases
began. By analogy, some investigators
believed that one agent couldbe developed
to cure turmors - the "magic bullet." This
view was not shared by Gilman and col-
leagues who noted the variation in lym-
phomas and stated that it was unlikely that
any compound would inhibit growth of all
cancer cells [35].
Following the introduction ofnitrogen
mustard into clinical practice, other types
of alkylating agents were developed many
of which are in clinical practice today,
most notably chlorambucil, melphalan,
busufan, and cyclophosphamide [43].
Interestingly the clinical spectrum of
their effectiveness is minimally changed
from the initial report, although the toxici-
ties differ.
The use of an antifolate compound
was reported by Sidney Farber, initiating
the development of antimetabolite therapy
[44]. This was followed by the use of
purine and pyrimidine analogs. Subse-
quently antitumor antibiotics, platinum
compounds, imidizole compounds, vinca
rosea alkaloids, taxols, camptothecin
analogs, and biologic agents have become
part ofthe therapeutic roster for neoplastic
diseases [45].
The search for an anticancer agent
that is selective for tumor, sparing normal
tissues, continues to the present day. The
vast increase in knowledge of biologic,
genetic and molecular aspects of neoplas-
tic disease has led to more specific forms
of therapy including targeted forms of
treatment, such as the anti-CD20 antibody
for lymphoid malignancies and most
recently STI 571 which is a specific
inhibitor of the BCL-ABL fusion gene
characterizing chronic myelogenous
leukemia [46, 47]. The long-term effects
of the newer targeted treatments had not
been defined, but they are more specific
and less toxic than conventional cytotoxic
agents whose discovery led to the modem
era of cancer treatment.
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